Similar considerations regarding a potential use for combating multidrug-resistant cancer were made for tazemetostat, a triple inhibitor of ABCB1, ABCC1 (multidrug resistance-associated protein 1, MRP1) and ABCG2 [28]. Here, ABCC1 is linked to cancer.